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To the editor:
Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed
gene expression on formalin-fixed paraffin-embedded biopsy specimens
The most frequent mature aggressive B-cell lymphomas are diffuse
large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).
Patients suffering from molecularly deﬁned BL (mBL) but treated
with a regimen developed for DLBCL show an unfavorable outcome
compared with mBL treated with chemotherapy regimens for BL.1
Distinguishing BL from DLBCL by conventional histopathology is
challenging in lymphomas that have features common to both diseases
(aggressive B-cell lymphoma unclassiﬁable with features of DLBCL
and BL [intermediates]).2 Moreover, DLBCLs are a heterogeneous
group of lymphomas comprising distinct molecular subtypes: the
activated B-cell–like (ABC), the germinal center B-cell–like (GCB),
and the unclassifyable subtype as deﬁned by gene expression proﬁl-
ing (GEP).3 Attempts to replace GEP with techniques applicable to
formalin-ﬁxed parafﬁn-embedded (FFPE) tissue led to algorithms for
immunohistochemical staining (IHS).4 Disappointingly, the algo-
rithms yielded conﬂicting results with respect to their prognostic
potential, raising concerns about their validity.5 Furthermore, IHS
algorithms did not provide a fully resolved classiﬁcation: they did not
identify mBL nor did they separate ABC from unclassiﬁed DLBCLs.4
We used digital multiplexed gene expression (DMGE) with
FFPE-derived RNA to classify agressive B-cell lymphomas. Our
assay comprised only 30 genes (10 for the detection of mBL and
20 for the detection of ABC and GCB). We chose these genes by
reanalysis of the microarray data reported in a previous study.6 A
detailed description of the methods is provided in the supplemental
Materials on the Blood website. Thirty-nine samples from mature
aggressive B-cell lymphomas were analyzed using DMGE (nCounter;
NanoString Technologies, Seattle, WA; see supplemental Materials
for detailed methods) of FFPE- and fresh-frozen–derived RNA. All
cases were previously characterized by the Molecular Mechanisms
of Malignant Lymphoma6 consortium using the Affymetrix GeneChip
technology (gold standard of classiﬁcation).
For FFPE-derived RNA, the classiﬁcation of only 2 of 39 samples
(5%) differed, when comparing DMGE-based predictions with the
gold standard (array) (Figure 1A). The 2 divergent classiﬁcations were
1 case of mBL that was classiﬁed as intermediate and 1 case of an
intermediate that was classiﬁed as mBL [both lymphomas carried a
t(8;14) translocation]. Nomajormistake (a classiﬁcation of a non-mBL
as mBL or vice versa) was observed. This performance is comparable
with that of DMGE data from fresh-frozen tissue blocks (supplemental
Materials). Compared with the array, 5 of 31 (16%) non-mBL/
DLBCLs received different molecular classiﬁcations using DMGE
and FFPE-derived RNA (Figure 1B). All discrepancies comprised
lymphomas that switched between the unclassiﬁed and ABC or un-
classiﬁed and GCB labels. Again, no major mistake (a classiﬁcation
of a GCB as an ABC or vice versa) was observed. In contrast, the
Hans IHS algorithm7 led to major mistakes (2 GCB classiﬁed as
non-GCB and 1 ABC as GCB; Figure 1B).
GEP-based molecular classiﬁcation of mature aggressive B-cell
lymphomas is possible with FFPE-derived RNA at a reasonable
cost (,100 Euro) and within a reasonable period of time (24 hours).
To the best of our knowledge, this is the ﬁrst molecular method
for identifying mBL among mature aggressive B-cell lymphomas
using FFPE-derived RNA.
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Figure 1. Digital multiplexed gene expression of mature aggressive B-cell lymphomas. (A) Molecular classification of mature aggressive B-cell lymphomas as mBL,
non-mBL, and intermediates using FFPE-derived RNA. The expression of the genes is color coded such that high expression is shown in yellow and low expression in blue.
The molecular labels assigned by the array using fresh-frozen RNA and DMGE (nCounter) assay using FFPE-derived RNA are indicated as colored labels in the top bars. (B)
Molecular classification of non-mBL using FFPE-derived RNA. The classification according to IHS (Hans), the array using fresh-frozen RNA and the DMGE assay using
FFPE-derived RNA are indicated as colored labels in the top bars.
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